Marcus Wallenberg - AstraZeneca PLC Non-Executive Director
| AZNN Stock | MXN 1,384 6.50 0.47% |
Director
Mr. Marcus Wallenberg is NonExecutive Director of AstraZeneca PLC. He has international business experience across various industry sectors, including the pharmaceutical industry from his directorship with Astra prior to 1999. Marcus is Chairman of Skandinaviska Enskilda Banken AB, Saab AB and FAM AB. He is a member of the boards of Investor AB, Temasek Holdings Limited, and the Knut and Alice Wallenberg Foundation. since 1999.
| Age | 63 |
| Tenure | 25 years |
| Phone | 44 20 3749 5000 |
| Web | https://www.astrazeneca.com |
AstraZeneca PLC Management Efficiency
The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Ian Davis | Johnson Johnson | 68 | |
| Anne Mulcahy | Johnson Johnson | 66 | |
| Jennifer Doudna | Johnson Johnson | 55 | |
| Mark McClellan | Johnson Johnson | 55 | |
| Marillyn Hewson | Johnson Johnson | 65 | |
| Charles Prince | Johnson Johnson | 69 | |
| Mary Beckerle | Johnson Johnson | 64 | |
| Ronald Williams | Johnson Johnson | 69 | |
| Iain Mackay | GlaxoSmithKline plc | 61 | |
Management Performance
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 |
AstraZeneca PLC Leadership Team
Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Dunoyer, Chief Financial Officer, Executive Director | ||
| Sherilyn McCoy, Non-Executive Independent Director | ||
| Genevieve Berger, Non-Executive Independent Director | ||
| Nazneen Rahman, Non-Executive Independent Director | ||
| Jose Baselga, Executive Vice President - Research & Development Oncology | ||
| Deborah Eldracher, Non-Executive Independent Director | ||
| Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer | ||
| Tony Mok, Non-Executive Independent Director | ||
| Fiona Cicconi, Executive Vice President - Human Resources | ||
| Deborah DiSanzo, Non-Executive Independent Director | ||
| Euan Ashley, Non-Executive Director | ||
| Chris Sheldon, Head Relations | ||
| Leif Johansson, Non-Executive Independent Chairman of the Board | ||
| Leon Wang, Executive Vice President - International and China President | ||
| Adrian Kemp, Company Secretary | ||
| Diana Layfield, Non-Executive Director | ||
| Michel Demare, Non-Executive Independent Director | ||
| Graham Chipchase, Senior Non-Executive Independent Director | ||
| Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee | ||
| Pam Cheng, Executive Vice-President of Operations and Information Technology | ||
| MBA DVM, CEO Director | ||
| Aradhana MD, CFO Director | ||
| Philip Broadley, Non-Executive Independent Director | ||
| Jeffrey Pott, General Counsel | ||
| Ruud Dobber, Executive Vice President, BioPharmaceuticals Business | ||
| David Fredrickson, Executive Vice-President Global Head Oncology Business Unit | ||
| Gonzalo Vina, Head Relations | ||
| Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals | ||
| Marcus Wallenberg, Non-Executive Director | ||
| Iskra Reic, Executive Vice President - Europe and Canada |
AstraZeneca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0863 | |||
| Return On Asset | 0.0531 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 4.74 T | |||
| Shares Outstanding | 3.1 B | |||
| Shares Owned By Insiders | 0.04 % | |||
| Shares Owned By Institutions | 17.94 % | |||
| Price To Earning | 39.41 X | |||
| Price To Book | 6.17 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.